JPWO2022101458A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022101458A5
JPWO2022101458A5 JP2023524957A JP2023524957A JPWO2022101458A5 JP WO2022101458 A5 JPWO2022101458 A5 JP WO2022101458A5 JP 2023524957 A JP2023524957 A JP 2023524957A JP 2023524957 A JP2023524957 A JP 2023524957A JP WO2022101458 A5 JPWO2022101458 A5 JP WO2022101458A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549316A (ja
JP2023549316A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/081610 external-priority patent/WO2022101458A1/en
Publication of JP2023549316A publication Critical patent/JP2023549316A/ja
Publication of JP2023549316A5 publication Critical patent/JP2023549316A5/ja
Publication of JPWO2022101458A5 publication Critical patent/JPWO2022101458A5/ja
Pending legal-status Critical Current

Links

JP2023524957A 2020-11-16 2021-11-15 Fapを標的としたcd40アゴニストとの併用療法 Pending JP2023549316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207768 2020-11-16
EP20207768.1 2020-11-16
PCT/EP2021/081610 WO2022101458A1 (en) 2020-11-16 2021-11-15 Combination therapy with fap-targeted cd40 agonists

Publications (3)

Publication Number Publication Date
JP2023549316A JP2023549316A (ja) 2023-11-24
JP2023549316A5 JP2023549316A5 (https=) 2024-11-20
JPWO2022101458A5 true JPWO2022101458A5 (https=) 2024-11-20

Family

ID=73452052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524957A Pending JP2023549316A (ja) 2020-11-16 2021-11-15 Fapを標的としたcd40アゴニストとの併用療法

Country Status (5)

Country Link
US (1) US20230340154A1 (https=)
EP (1) EP4244254A1 (https=)
JP (1) JP2023549316A (https=)
CN (1) CN117916261A (https=)
WO (1) WO2022101458A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
KR20250153216A (ko) * 2023-02-24 2025-10-24 상하이 맙젠 바이오텍 리미티드 Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
AR134514A1 (es) 2023-12-01 2026-01-21 Gilead Sciences Inc Proteína de fusión anti-fap-ligera y uso de esta
WO2025255349A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2026052650A1 (en) * 2024-09-05 2026-03-12 F. Hoffmann-La Roche Ag Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-p-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
HUE036077T2 (hu) * 2010-08-13 2018-06-28 Roche Glycart Ag Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
SG10201602394QA (en) 2011-03-29 2016-05-30 Roche Glycart Ag Antibody FC Variants
AU2018247796A1 (en) * 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
NZ773887A (en) * 2018-10-01 2024-11-29 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-fap clone 212
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40

Similar Documents

Publication Publication Date Title
RU2019123613A (ru) Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
JP2020520370A5 (https=)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2017512765A5 (https=)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
JP2024056687A5 (https=)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2020500834A5 (https=)
JP2010520290A5 (https=)
IL276675B1 (en) Anti-pd-1 antibodies and uses thereof
JP2022521305A (ja) 抗pd-l1抗体及びその使用
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
JPWO2022101458A5 (https=)
CA2538725A1 (en) Nogo-a binding molecules and pharmaceutical use thereof
CN101233155B (zh) 人抗表皮生长因子受体抗体
JPWO2022256559A5 (https=)
JPWO2022104236A5 (https=)
JPWO2023098888A5 (https=)
JPWO2022159984A5 (https=)
JPWO2021190622A5 (https=)
JPWO2020143749A5 (https=)
JPWO2021173832A5 (https=)
JPWO2021186427A5 (https=)
JPWO2023161457A5 (https=)
JPWO2021139780A5 (https=)